NCT07418450 Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?
| NCT ID | NCT07418450 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Vienna |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-05 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-11-05 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.
Eligibility Criteria
Inclusion Criteria: * Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer * indication for mediastinal staging Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07418450 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07418450 currently recruiting?
Yes, NCT07418450 is actively recruiting participants. Contact the research team at daniela.gompelmann@meduniwien.ac.at for enrollment information.
Where is the NCT07418450 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT07418450 clinical trial?
NCT07418450 is sponsored by University of Vienna. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.